Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation: 2017-2024

Historic Share-based Compensation for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $30.7 million.

  • Kiniksa Pharmaceuticals International's Share-based Compensation rose 29.62% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year increase of 16.24%. This contributed to the annual value of $30.7 million for FY2024, which is 13.05% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Share-based Compensation of $30.7 million as of FY2024, which was up 13.05% from $27.1 million recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Share-based Compensation peaked at $30.7 million during FY2024, and registered a low of $20.9 million during FY2020.
  • Its 3-year average for Share-based Compensation is $27.7 million, with a median of $27.1 million in 2023.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Share-based Compensation spiked by 38.43% in 2020 and then declined by 0.21% in 2022.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Share-based Compensation (Yearly) stood at $20.9 million in 2020, then grew by 20.59% to $25.2 million in 2021, then declined by 0.21% to $25.1 million in 2022, then grew by 8.08% to $27.1 million in 2023, then rose by 13.05% to $30.7 million in 2024.